Ensign Peak Advisors, Inc Celldex Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 23,428 shares of CLDX stock, worth $486,833. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,428
Previous 23,428
-0.0%
Holding current value
$486,833
Previous $795,000
25.53%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CLDX
# of Institutions
196Shares Held
60.7MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$105 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$97.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$80.7 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$78 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$73.9 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $972M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...